|
 |
- Capecitabine/docetaxel (XT) versus docetaxel
alone in metastatic disease |
| |
- Phase II trials comparing capecitabine to
paclitaxel or CMF in patients with metastatic
disease |
| |
- NSABP neoadjuvant XT trial |
| |
- US Oncology adjuvant XT trial |
| |
- Adjuvant taxanes in ER/PR-positive patients |
| |
- Potential synergy of trastuzumab/gemcitabine |
| |
- Duration of trastuzumab therapy |
| |
Recent publications
of capecitabine in the treatment of breast cancer |
| |
|
- HER2 assessment |
| |
- Management of patients with HER2-positive metastatic
breast cancer |
| |
- Duration of trastuzumab therapy |
| |
- Investigating relationships between HER2 and
other signaling pathways |
| |
- Clinical implications of the ATAC trial results |
| |
- Management of patients with HER2-negative, ER-negative
metastatic breast cancer |
| |
- Single-agent versus combination chemotherapy
for metastatic disease |
| |
Recent
and key publications regarding trastuzumab for the
treatment of metastatic breast cancer |
| |
|
|
- Combined data from the trials of fulvestrant
versus anastrozole |
| |
- Fulvestrant: Mechanism of action and questions
for the future |
| |
- Response to endocrine therapy after treatment
with fulvestrant |
| |
- Fulvestrant in premenopausal women |
| |
- Interpreting the ATAC trial results |
| |
- Clinical management in light of the ATAC trial
results |
| |
- Substituting other aromatase inhibitors for
anastrozole |
| |
Select publications
regarding fulvestrant |
| |
|
Breast Cancer Update: A
CME Audio Series and Activity
Faculty Financial:
Interest or Affiliations
|
|
|
|
